Hereditary Cancer DNA Test Panel (Whole Exome Sequencing)

Comprehensive Hereditary Cancer Panel India with Whole Exome Sequencing

Whole Exome based analysis covering genes for various types of cancer

Proactive Care Starts with Understanding Your Genes

A family history of cancer doesn't have to be a source of constant worry. The MapmyGenome Hereditary Cancer Panel is an advanced, Whole Exome Sequencing-based DNA test designed to identify genetic mutations linked to an increased risk of developing various hereditary cancers.

Armed with this knowledge, you and your doctor can create a highly personalized, proactive roadmap for early detection and prevention.

Why Choose This Test?

• Advanced Technology: Utilizes high-resolution Whole Exome Sequencing for maximum accuracy.

• Comprehensive Screening: Analyzes over 100 specific genes associated with breast, ovarian, colorectal, prostate, pancreatic, and other hereditary cancers.

• Expert Guidance Included: We don’t just hand you a complex report. Every test includes a free, 1-on-1 consultation with a certified Genetic Counselor to help you understand your results and plan your next steps.

• 100% Privacy & Security: Your DNA and data are analyzed in our NABL-accredited labs with strict confidentiality protocols.

Who Should Take This Test?

This panel is highly recommended if you have:

• A personal or family history of cancer (especially if diagnosed at an early age).

• Multiple family members on the same side of the family diagnosed with the same or related cancers.

• A known genetic mutation in your family (e.g., BRCA1, BRCA2, Lynch Syndrome).

What Genes are Covered?
Our high-density panel screens for critical markers, including but not limited to:

• Breast & Ovarian: BRCA1, BRCA2, PALB2, CHEK2, PTEN

• Colorectal (Lynch Syndrome): MLH1, MSH2, MSH6, PMS2, EPCAM

• Comprehensive List: AAIP, ALK, APC, AR, ATM, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CD82, CDC73, CDH1, CDK4, CDKN1C, CDKN2A, CEBPA, CEP57, CHEK2, CYLD, DDB2, DICER1, DIS3L2, EGFR, ELAC2, ENG, EPCAM, ERCC2, ERCC3, ERCC4, ERCC5, EXT1, EXT2, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FH, FLCN, GATA2, GPC3, HRAS, KIT, MAX, MEN1, MET, MLH1, MLH3, MRE11A, MSH2, MSH3, MSH6, MSR1, MUTYH, MXI1, NBN, NF1, NF2, NSD1, PALB2, PHOX2B, PMS1, PMS2, PRF1, PRKAR1A, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RB1, RECQL4, RET, RHBDF2, RNASEL, RUNX1, SBDS, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCB1, STK11, SUFU, TGFBR2, TMEM127, TP53, TSC1, TSC2, VHL, WRN, WT1, XPA, XPC
  
  "Want to consult your physician first? 📄 Download the Hereditary Cancer Panel Doctor's Brochure"
  

What is the Hereditary Cancer Panel India?

The hereditary cancer panel India offers a specialized genetic test designed to identify inherited mutations linked to various cancers. Using advanced whole exome sequencing technology, this panel analyzes thousands of genes to detect variations that may increase an individual's cancer risk. This precise testing enables early diagnosis and personalized treatment options, empowering patients and doctors with crucial information about hereditary cancer predispositions. Ordering this test in India ensures access to cutting-edge genetic analysis performed by expert laboratories, making it an essential tool for comprehensive cancer risk assessment.

Advantages of Whole Exome Sequencing in Cancer Testing

Whole exome sequencing (WES) is a highly efficient method that targets all protein-coding regions of the genome, which is where most disease-causing mutations are found. This approach provides a detailed genetic profile and uncovers rare or novel mutations that other methods might miss. In the context of hereditary cancer panel India, WES delivers deep insights into multiple cancer-related genes simultaneously. The detailed data generated allows clinicians to develop targeted prevention strategies and personalized therapies, making it a powerful resource for patient-centric cancer care and improved health outcomes.

Who Should Consider the Hereditary Cancer DNA Test?

Individuals with a family history of cancer or multiple cancer types are ideal candidates for the hereditary cancer panel India. It is particularly recommended for those with early-onset cancer or cancers known to have hereditary links, such as breast, ovarian, colon, or prostate cancer. Genetic counseling alongside testing helps patients understand the implications of their results and guides them in making informed decisions about their health. By identifying genetic risk factors early, patients can benefit from tailored screening protocols and preventive measures, which can significantly reduce cancer incidence and improve long-term survival rates.